817 related articles for article (PubMed ID: 30718832)
1. Molecular subtypes of pancreatic cancer.
Collisson EA; Bailey P; Chang DK; Biankin AV
Nat Rev Gastroenterol Hepatol; 2019 Apr; 16(4):207-220. PubMed ID: 30718832
[TBL] [Abstract][Full Text] [Related]
2. The need for effective pancreatic cancer detection and management: a biomarker-based strategy.
Crawley AS; O'Kennedy RJ
Expert Rev Mol Diagn; 2015; 15(10):1339-53. PubMed ID: 26394703
[TBL] [Abstract][Full Text] [Related]
3. Molecular landscape of pancreatic cancer: challenges and clinical implications.
Kyrochristos ID; Ziogas DE; Glantzounis GK; Roukos DH
Future Oncol; 2017 Dec; 13(30):2741-2744. PubMed ID: 29182377
[No Abstract] [Full Text] [Related]
4. Cyst fluid biomarkers for intraductal papillary mucinous neoplasms of the pancreas: a critical review from the international expert meeting on pancreatic branch-duct-intraductal papillary mucinous neoplasms.
Maker AV; Carrara S; Jamieson NB; Pelaez-Luna M; Lennon AM; Dal Molin M; Scarpa A; Frulloni L; Brugge WR
J Am Coll Surg; 2015 Feb; 220(2):243-53. PubMed ID: 25592469
[No Abstract] [Full Text] [Related]
5. Exosomes in the Treatment of Pancreatic Cancer: A Moonshot to PDAC Treatment?
Papadakos SP; Dedes N; Pergaris A; Gazouli M; Theocharis S
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408980
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers for subtypes of pancreatic ductal adenocarcinoma.
Venkatesan P
Lancet Oncol; 2017 Dec; 18(12):e718. PubMed ID: 29129444
[No Abstract] [Full Text] [Related]
7. Biomarkers, imaging and multifocality in intraductal papillary mucinous neoplasms: relevant for decision making?
Ansari D; Aronsson L; Andersson R
Future Oncol; 2017 Aug; 13(20):1751-1753. PubMed ID: 28831817
[No Abstract] [Full Text] [Related]
8. Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response.
Muckenhuber A; Berger AK; Schlitter AM; Steiger K; Konukiewitz B; Trumpp A; Eils R; Werner J; Friess H; Esposito I; Klöppel G; Ceyhan GO; Jesinghaus M; Denkert C; Bahra M; Stenzinger A; Sprick MR; Jäger D; Springfeld C; Weichert W
Clin Cancer Res; 2018 Jan; 24(2):351-359. PubMed ID: 29101303
[No Abstract] [Full Text] [Related]
9. Advancing on pancreatic cancer.
Nat Rev Gastroenterol Hepatol; 2021 Jul; 18(7):447. PubMed ID: 34188210
[No Abstract] [Full Text] [Related]
10. Identifying molecular subtypes related to clinicopathologic factors in pancreatic cancer.
Kim S; Kang M; Lee S; Bae S; Han S; Jang JY; Park T
Biomed Eng Online; 2014; 13 Suppl 2(Suppl 2):S5. PubMed ID: 25560450
[TBL] [Abstract][Full Text] [Related]
11. Role of non-coding RNAs in pancreatic cancer: the bane of the microworld.
Tang YT; Xu XH; Yang XD; Hao J; Cao H; Zhu W; Zhang SY; Cao JP
World J Gastroenterol; 2014 Jul; 20(28):9405-17. PubMed ID: 25071335
[TBL] [Abstract][Full Text] [Related]
12. Genetically engineered mouse models of pancreatic cancer: unravelling tumour biology and progressing translational oncology.
Mazur PK; Siveke JT
Gut; 2012 Oct; 61(10):1488-500. PubMed ID: 21873467
[TBL] [Abstract][Full Text] [Related]
13. Clinical Value of Circulating miRNA in Diagnosis, Prognosis, Screening and Monitoring Therapy of Pancreatic Ductal Adenocarcinoma-A Review of the Literature.
Wnuk J; Strzelczyk JK; Gisterek I
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982210
[TBL] [Abstract][Full Text] [Related]
14. Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy.
Li R; He Y; Zhang H; Wang J; Liu X; Liu H; Wu H; Liang Z
Front Immunol; 2021; 12():690056. PubMed ID: 34335594
[TBL] [Abstract][Full Text] [Related]
15. Early detection of sporadic pancreatic cancer: summative review.
Chari ST; Kelly K; Hollingsworth MA; Thayer SP; Ahlquist DA; Andersen DK; Batra SK; Brentnall TA; Canto M; Cleeter DF; Firpo MA; Gambhir SS; Go VL; Hines OJ; Kenner BJ; Klimstra DS; Lerch MM; Levy MJ; Maitra A; Mulvihill SJ; Petersen GM; Rhim AD; Simeone DM; Srivastava S; Tanaka M; Vinik AI; Wong D
Pancreas; 2015 Jul; 44(5):693-712. PubMed ID: 25931254
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic cancer early detection: expanding higher-risk group with clinical and metabolomics parameters.
Urayama S
World J Gastroenterol; 2015 Feb; 21(6):1707-17. PubMed ID: 25684935
[TBL] [Abstract][Full Text] [Related]
17. Early detection of sporadic pancreatic cancer: strategic map for innovation--a white paper.
Kenner BJ; Chari ST; Cleeter DF; Go VL
Pancreas; 2015 Jul; 44(5):686-92. PubMed ID: 25938853
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Stratification Based on HIF-1 Signaling for Evaluating Hypoxic Status and Immune Infiltration in Pancreatic Ductal Adenocarcinomas.
Zhuang H; Wang S; Chen B; Zhang Z; Ma Z; Li Z; Liu C; Zhou Z; Gong Y; Huang S; Hou B; Chen Y; Zhang C
Front Immunol; 2021; 12():790661. PubMed ID: 34925373
[TBL] [Abstract][Full Text] [Related]
19. Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes.
Zhao L; Zhao H; Yan H
BMC Cancer; 2018 May; 18(1):603. PubMed ID: 29843660
[TBL] [Abstract][Full Text] [Related]
20. A preoperative risk model for early recurrence after radical resection may facilitate initial treatment decisions concerning the use of neoadjuvant therapy for patients with pancreatic ductal adenocarcinoma.
Guo SW; Shen J; Gao JH; Shi XH; Gao SZ; Wang H; Li B; Yuan WL; Lin L; Jin G
Surgery; 2020 Dec; 168(6):1003-1014. PubMed ID: 32321665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
